Company Overview and News
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains and was up 0.28% at midday break, while remaining above the crucial 1,800-point level, in line with the advance at most regional markets.
HLFBF APEXF 7052 5183 7090 GMALF PECGF 1082 2291 0096 5256 9334 5134 7277 5199 GMALY 5436 4588 3026 4715 5819 2836 HIPEF
(Sept 20): Most Southeast Asian stock markets rose on Thursday, in line with Asian peers and overnight gains on Wall Street, while investors took heart as Sino-U.S. trade war pressures seemed to have eased.
GMALY SMPH ICT 4715 GMALF SPHXY SPHXF ICTEF SPHZF
KUALA LUMPUR (Sept 20): The FBM KLCI rose 0.46% at mid-morning, tracking gains at the regional markets, lifted by select index-linked blue chips.
HLFBF 7052 GMALF 1082 BATS 4162 0096 5256 5199 GMALY 5139 5258 3301 4715 0900 5208 5819 2836 HIPEF
Genting Malaysia Bhd (Sept 18, RM4.87) Maintain buy with an unchanged target price of RM5.70: Genting Malaysia Bhd has announced that the US federal government, via the Department of Interior (DoI), had recently issued a decision stating that the Mashpee Wampanoag Tribe would not be granted the disputed land in trust for developing the First Light Resort & Casino (FLRC) in Taunton, south of Boston, the US.
GMALY 4715 GMALF
Visitor count to the hilltop resort increased by 21% year-on-year to 12.8 million as of June, due to the new facilities opened under the Genting Integrated Transformation Plan that included the SkyCasino, SkyAvenue mall and Awana Skyway cable car.
GMALY 4715 GMALF
KUALA LUMPUR (Sept 18): The FBM KLCI is expected trade range bound today and hover around the 1,800-point level today, given the positive domestic sentiment after Morgan Stanley last week upgraded Malaysia stocks to equal weight
GMALF 7006 9598 GMALY 4995 4715 7208 MS
KUALA LUMPUR (Sept 14): Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (Sept 18) may include the following: Tropicana Corp Bhd, Latitude Tree Holdings Bhd, Versatile Creative Bhd, Vertice Bhd, Euro Holdings Bhd, Genting Malaysia Bhd, Gamuda Bhd and Pintaras Jaya Bhd.
GMALY 4995 4715 GMALF 7208 7006 BSMAF 9598 1818
KUALA LUMPUR (Sept 14): Genting Malaysia Bhd (GENM), which had subscribed to promissory notes issued by the Mashpee Wampanoag Tribe in the US in 2016 for an integrated gaming resort development in the US, said it is still deliberating the appropriate course of action for its investment in the promissory notes, as well as its recoverability.
GMALY 4715 GMALF BSMAF 1818
KUALA LUMPUR: Bursa Malaysia once again showed an uncertain start with a positive showing at the opening bell that quickly descended into the red. The mood among investors in Asian markets were expected to pick up on Thursday as US officials extended another invitation to China to hold bilateral talks in an effort to resolve the current trade dispute. Wall Street had picked up slightly overnight on news of the trade talks while Japan's Nikkei rose about 1% in early Thursday trade.
GMALY TGLVY PBLOF 4715 GMALF 7113 TPGVF 1295 BSMAF 1818
KUALA LUMPUR (Aug 30): The FBM KLCI pared losses for a 1.01-point or 0.06% drop after volatile trade as investors evaluated Malaysian corporate earnings and as China-US trade spat concerns lingered.
GMALY 4715 GMALF 5819
KUALA LUMPUR: Econpile Holdings Bhd , Destini Bhd , Sentoria Group Bhd and Dayang Enterprise Holdings Bhd are among the stocks to watch today, according to JF Apex Research.
4634 GMALY BSTHY 4715 GMALF 5253 5141 5213 2771 GEBHF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET